Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | KMT2A rearrange |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
KMT2A rearrange | leukemia | predicted - sensitive | Doxorubicin + I-CBP112 | Preclinical | Actionable | In a preclinical study, I-CBP112 sensitized leukemia cells harboring KMT2A fusions to Doxorubicin, leading to decreased cell growth in culture (PMID: 26552700). | 26552700 | |
KMT2A rearrange | leukemia | predicted - sensitive | I-CBP112 + JQ1 | Preclinical | Actionable | In a preclinical study, I-CBP112 sensitized leukemia cells harboring KMT2A fusions to JQ1, resulting in decreased cell growth in culture (PMID: 26552700). | 26552700 | |
KMT2A rearrange | acute lymphoblastic leukemia | sensitive | Cytarabine + Panobinostat | Preclinical - Cell culture | Actionable | In a preclinical study, Farydak (panobinostat) enhanced the effects of Cytosar-U (cytarabine) in acute lymphoblastic leukemia cells harboring a KMT2A rearrangement in culture, resulting in cell death (PMID: 27443263). | 27443263 | |
KMT2A rearrange | acute lymphoblastic leukemia | sensitive | Cytarabine + Mocetinostat | Preclinical - Cell culture | Actionable | In a preclinical study, Mocetinostat (MGCD0103) enhanced the effects of Cytosar-U (cytarabine) in acute lymphoblastic leukemia cell lines harboring a KMT2A rearrangement in culture, resulting in cell death (PMID: 27443263). | 27443263 | |
KMT2A rearrange | acute lymphoblastic leukemia | sensitive | Cytarabine + Dacinostat | Preclinical - Cell culture | Actionable | In a preclinical study, Dacinostat (LAQ824) enhanced the effects of Cytosar-U (cytarabine) in acute lymphoblastic leukemia cell lines harboring a KMT2A rearrangement in culture, resulting in cell death (PMID: 27443263). | 27443263 | |
KMT2A rearrange | acute lymphoblastic leukemia | sensitive | Cytarabine + Romidepsin | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Istodax (romidepsin) enhanced the effects of Cytosar-U (cytarabine) in acute lymphocytic leukemia cell lines harboring a KMT2A rearrangement in culture, and in cell line xenograft models, demonstrating decreased leukemic cells by 73% (PMID: 27443263). | 27443263 | |
KMT2A rearrange | acute lymphoblastic leukemia | decreased response | Romidepsin | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Istodax (romidepsin) resulted in minimal activity in acute lymphocytic leukemia cell lines harboring a KMT2A rearrangement in culture, and in cell line xenograft models, demonstrating decreased leukemic cells by 16% (PMID: 27443263). | 27443263 | |
KMT2A rearrange | acute lymphoblastic leukemia | sensitive | Cytarabine | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Cytosar-U (cytarabine) decreased leukemic cells by 66% in acute lymphocytic leukemia cell line xenograft models harboring a KMT2A rearrangement (PMID: 27443263). | 27443263 | |
KMT2A rearrange | acute myeloid leukemia | predicted - sensitive | KO-539 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, KO-539 inhibited growth of KMT2A (MLL1)-rearranged acute myeloid leukemia cells in culture, and prolonged survival in cell-line xenograft models (AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-A27). | detail... | |
KMT2A rearrange | acute leukemia | predicted - sensitive | Pinometostat | Case Reports/Case Series | Actionable | In a Phase I trial, Pinometostat (EPZ-5676) treatment resulted in complete remission in 2 patients with KMT2A rearranged (both with t(11;19)) acute leukemia (PMID: 29724899; NCT01684150). | 29724899 | |
KMT2A rearrange | acute myeloid leukemia | sensitive | CYC065 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, CYC065 (Fadraciclib) treatment resulted in decreased cell viability in an acute myeloid leukemia cell line harboring a KMT2A rearrangement in culture and inhibited tumor growth in a cell line xenograft model (PMID: 32645016). | 32645016 | |
KMT2A rearrange | acute lymphoblastic leukemia | predicted - sensitive | CYC065 | Preclinical - Cell culture | Actionable | In a preclinical study, acute lymphoblastic leukemia cell lines harboring KMT2A rearrangements were sensitive to treatment with CYC065 (Fadraciclib) in culture (PMID: 32645016). | 32645016 | |
KMT2A rearrange | acute leukemia | predicted - sensitive | Revumenib | Phase I | Actionable | In a Phase I trial (AUGMENT 101), Revumenib treatment demonstrated acceptable safety and promising antileukemic activity in patients with acute leukemia harboring KMT2A rearrangements, and led to a composite complete response rate of 49% (17/35) (Blood (2021) 138 (Supplement 1): 699). | detail... | |
KMT2A rearrange | acute myeloid leukemia | predicted - sensitive | Revumenib | Case Reports/Case Series | Actionable | In a Phase I trial (AUGMENT-101), Revumenib treatment resulted in an initial response with morphological leukemia-free states in 2 patients with acute myeloid leukemia harboring KMT2A rearrangements (PMID: 36922589; NCT04065399). | 36922589 | |
KMT2A rearrange | acute myeloid leukemia | not applicable | N/A | Clinical Study | Prognostic | In multiple clinical studies, KMT2A rearrangements, specifically partial tandem duplications, were associated with a poor overall survival in acute myeloid leukemia patients (PMID: 24487413, PMID: 22915647, PMID: 22417203, PMID: 21881046). | 21881046 24487413 22417203 22915647 | |
KMT2A rearrange | acute myeloid leukemia | not applicable | N/A | Guideline | Prognostic | KMT2A rearrangements (t(v;11q23.3)) are associated with a poor/adverse prognosis in patients with non-APL acute myeloid leukemia (NCCN.org). | detail... | |
KMT2A rearrange | childhood B-cell acute lymphoblastic leukemia | not applicable | N/A | Guideline | Prognostic | KMT2A rearrangements are associated with a poor prognosis in pediatric patients with B-cell acute lymphoblastic leukemia (NCCN.org). | detail... | |
KMT2A rearrange | B-cell acute lymphoblastic leukemia | not applicable | N/A | Guideline | Prognostic | KMT2A rearrangements are associated with a poor prognosis in patients with B-cell acute lymphoblastic leukemia (NCCN.org). | detail... |